or Try an Advanced Search...

    Technical Analysis for OCGN - Ocugen, Inc.

    Grade Last Price % Change Price Change
    B 1.72 9.55% 0.15
    OCGN closed up 9.55 percent on Wednesday, May 8, 2024, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical OCGN trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Wide Bands Range Expansion 9.55%
    Crossed Above 20 DMA Bullish 5.52%
    MACD Bullish Centerline Cross Bullish 5.52%
    MACD Bullish Signal Line Cross Bullish 5.52%
    180 Bullish Setup Bullish Swing Setup 5.52%
    Pocket Pivot Bullish Swing Setup 5.52%
    Older End-of-Day Signals for OCGN ...

       Recent Intraday Alerts

    Alert Time
    Up 1 ATR about 9 hours ago
    Possible Pocket Pivot about 9 hours ago
    Rose Above Previous Day's High about 12 hours ago
    Up 10% about 12 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OCGN Chart by TradingView
    Basic chart:

    Profile

    Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa

    Is OCGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 3 Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
    May 2 Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 29 Can Ocugen Stock Keep Churning Higher?
    Apr 29 Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
    Apr 26 Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
    Apr 26 UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    Apr 26 Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    Apr 19 Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
    Apr 19 Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
    See more OCGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.105
    52 Week Low 0.345
    Average Volume 9,334,683
    200-Day Moving Average 0.70
    50-Day Moving Average 1.35
    20-Day Moving Average 1.42
    10-Day Moving Average 1.41
    Average True Range 0.18
    RSI (14) 62.26
    ADX 22.52
    +DI 27.53
    -DI 12.86
    Chandelier Exit (Long, 3 ATRs) 1.38
    Chandelier Exit (Short, 3 ATRs) 1.65
    Upper Bollinger Bands 1.77
    Lower Bollinger Band 1.07
    Percent B (%b) 0.92
    BandWidth 49.40
    MACD Line 0.04
    MACD Signal Line 0.01
    MACD Histogram 0.0286
    Fundamentals Value
    Market Cap 441.18 Million
    Num Shares 257 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -5.38
    Price-to-Sales 25069.32
    Price-to-Book 2.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.08
    Resistance 3 (R3) 2.05 1.90 2.02
    Resistance 2 (R2) 1.90 1.81 1.92 2.00
    Resistance 1 (R1) 1.81 1.75 1.86 1.84 1.98
    Pivot Point 1.66 1.66 1.68 1.68 1.66
    Support 1 (S1) 1.57 1.57 1.62 1.60 1.46
    Support 2 (S2) 1.42 1.51 1.44 1.44
    Support 3 (S3) 1.33 1.42 1.42
    Support 4 (S4) 1.36